A. Ten Brinke (Leeuwarden, Netherlands), A. Papaioannou (Vrilissia (Athens), Greece)
Longitudinal characteristics of the Severe Asthma Research Program (SARP) clinical clusters
X. Li (Tucson, United States of America), W. Moore (Winston-Salem, United States of America), H. Li (Tucson, United States of America), W. Busse (Madison, United States of America), M. Castro (Kansas City, United States of America), S. Erzurum (Cleveland, United States of America), J. Fahy (San Francisco, United States of America), B. Gaston (Cleveland, United States of America), E. Israel (Boston, United States of America), N. Jarjour (Madison, United States of America), B. Levy (Boston, United States of America), S. Wenzel (Pittsburgh, United States of America), D. Meyers (Tucson, United States of America), E. Bleecker (Tucson, United States of America)
|     |
Effect of maintenance oral corticosteroids on risk factors for frequent exacerbations in a severe adult asthma population
J. Yang (Glagow, United Kingdom), J. Busby (Belfast, United Kingdom), L. Heaney (Belfast, United Kingdom), P. Pfeffer (London, United Kingdom), D. Jackson (London, United Kingdom), A. Mansur (Birmingham, United Kingdom), A. Menzies-Gow (London, United Kingdom), S. Siddiqui (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom), R. Niven (Manchester, United Kingdom), M. Patel (Plymouth, United Kingdom), N. Thomson (Glasgow, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom)
| |
Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify asthma-COPD overlap
T. Shirai (Shizuoka, Japan), K. Hirai (Shizuoka, Japan), Y. Gon (Tokyo, Japan), S. Maruoka (Tokyo, Japan), K. Mizumura (Tokyo, Japan), M. Hikichi (Tokyo, Japan), K. Itoh (Shizuoka, Japan), S. Hashimoto (Tokyo, Japan)
| |
Real world residual disease manifestations after 2-years anti-IL-5 treatment for severe asthma
K. Eger (Amsterdam, Netherlands), J. Kroes (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), J. Sont (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands)
| |
Categorization of asthma patients by Global Initiative for Asthma (GINA) 2018 guidelines using a US administrative claims database
M. Castro (Kansas City, United States of America), M. Mychaskiw (West Chester, United States of America), S. Lim (West Chester, United States of America), R. Brown (West Chester, United States of America), S. Colilla (West Chester, United States of America)
| |
Histopathological comparison of endobronchial biopsies from different pulmonary lobes of severe asthmatic patients
M. Karakioulaki (Basel, Switzerland), T. Koletsa (Thessaloniki, Greece), E. Papakonstantinou (Basel, Switzerland), S. Savic (Basel, Switzerland), K. Jahn (Basel, Switzerland), M. Tamm (Basel, Switzerland), D. Stolz (Basel, Switzerland)
| |
Impact of the eosinophil variability on severe exacerbations in an asthmatic population
N. Toledo Pons (Palma De Mallorca, Spain), J. Van Boven (Groningen, Netherlands), J. Muncunill Farreny (Palma, Spain), A. Millán Pons (Palma, Spain), M. Román Rodríguez (Palma, Spain), B. López Andrade (Palma, Spain), J. Kocks (Groninegen, Netherlands), B. García-Cosío Piqueras (Palma, Spain)
| |